With Eye On FDA, Kite Says CAR-T For Lymphoma Holds Up After 6 Months – Xconomy
Xconomy |
With Eye On FDA, Kite Says CAR–T For Lymphoma Holds Up After 6 Months
Xconomy The patients were treated with a single dose of their own T cells and no other follow-up treatments, according to Kite officials. In CAR–T cell therapy, a patients' T cells are extracted and genetically modified outside the body to become more … Kite's CAR–T cancer therapy shows strong results as company races to win FDA approval Kite Pharma CAR–T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients Kite's shares fly high after cancer drug clears main study goal |
